Login / Signup

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma.

Emeline ColombaCarolina Alves Costa SilvaGwénaël Le TeuffJamie ElmawiehDaniel AfonsoAxelle Benchimol-ZouariAnnalisa GuidaLisa DerosaRonan FlippotBruno RaynardBernard EscudierFrançois BidaultLaurence Albiges
Published in: Journal of cachexia, sarcopenia and muscle (2022)
We report a high incidence of grades 3-4 WL, fourth times higher than reported in prior pivotal trials, and half of the patients developed sarcopenia while on cabozantinib treatment. Weight and muscle mass loss with cabozantinib are underreported and may require further investigations and early management.
Keyphrases